Yvonne M H Versleijen-Jonkers

9PUBLICATIONS
67CO-AUTHORS
Haematological tumoursSocial epidemiologyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 09, 2025
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.

Stefan G van Ravensteijn, Jacco J de Haan, Hans Gelderblom

|Jul 14, 2023
Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases.

Tess Tomassen, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen

|Jun 22, 2023
The Prognostic Relevance of MRI Characteristics in Myxofibrosarcoma Patients Treated with Neoadjuvant Radiotherapy.

Stefan G van Ravensteijn, Maikel J L Nederkoorn, Tom C P Wal

|Dec 11, 2022
Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups.

Stefan G van Ravensteijn, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen

|Jun 03, 2022
Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma.

Anke E M van Erp, Melissa H S Hillebrandt-Roeffen, Niek F H N van Bree

|Mar 10, 2022
Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study.

Chiel A J van der Horst, Sabien L M Bongers, Yvonne M H Versleijen-Jonkers

Pageof 2